Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

Fifteen cases were identified, spanning argyrophilic grain disease, primary age-related tauopathy, corticobasal degeneration, genetic frontotemporal dementia, and progressive supranuclear palsy. The mean age of onset was 69 years, with average survival of 6 years. Notably, only 47% of cases showed concordance between clinical and pathological diagnosis, underscoring diagnostic challenges. Neuropathological review revealed marked diversity in tau pathology and regional vulnerability, with most cases demonstrating both neuronal and glial tau pathology. This case series highlights the complexity and heterogeneity of primary tauopathies and the critical role of post-mortem neuropathological examination for diagnosis. By making fixed and frozen tissue, and clinical data available for national and international dissemination, this study provides a valuable resource to advance global research into the pathogenesis and classification of tauopathies. Furthermore, this work highlights the important role of brain banking in the study of rare diseases.

What this study adds

Evidence grade: Low

In this brain bank series of 15 cases, only 47% showed agreement between clinical and pathological diagnosis, showing how hard these diseases are to diagnose in life. The study provides tissue and clinical data for research, but does not test any treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ryan, B., Marriott, L., Murray, H. C., Faull, R. L. M., Turner, C. P., & Curtis, M. A. (2026). Clinicopathological features of primary tauopathies: a brain bank series. Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1768959

Vancouver

Ryan B, Marriott L, Murray HC, Faull RLM, Turner CP, Curtis MA. Clinicopathological features of primary tauopathies: a brain bank series. Frontiers in Neurology. 2026. doi:10.3389/fneur.2026.1768959. PMID: 41982423.

BibTeX

@article{ryan2026-41982423,
  author  = {Ryan, Brigid and Marriott, Laura and Murray, Helen C. and Faull, Richard L. M. and Turner, Clinton P. and Curtis, Maurice A.},
  title   = {{Clinicopathological features of primary tauopathies: a brain bank series}},
  journal = {Frontiers in Neurology},
  year    = {2026},
  doi     = {10.3389/fneur.2026.1768959},
  pmid    = {41982423},
  url     = {https://doi.org/10.3389/fneur.2026.1768959}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this brain bank series of 15 cases, only 47% showed agreement between clinical and pathological diagnosis, showing how hard these diseases are to diagnose in life. The study provides tissue and clinical data for research, but does not test any treatment, cure or prevention.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Neurology)
Journal's citation record 2 / 4 Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 4.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Maurice A. Curtis: h-index 52 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Auckland: institution h-index 788 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41982423)
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →